StockNews.com Upgrades Repligen (NASDAQ:RGEN) to “Hold”

Repligen (NASDAQ:RGEN) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

Other research analysts also recently issued reports about the stock. Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target for the company. JPMorgan Chase & Co. lifted their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Stephens restated an “overweight” rating and issued a $170.00 target price on shares of Repligen in a research note on Tuesday, July 30th. Benchmark reiterated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Repligen presently has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $142.43 on Wednesday. The stock has a fifty day moving average of $141.59 and a 200-day moving average of $144.78. The stock has a market cap of $7.98 billion, a PE ratio of -389.94, a price-to-earnings-growth ratio of 4.27 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $211.13.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same quarter in the previous year, the firm earned $0.23 EPS. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. Equities research analysts anticipate that Repligen will post 1.45 earnings per share for the current year.

Insider Activity

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Repligen

Several institutional investors have recently bought and sold shares of the stock. Andra AP fonden purchased a new stake in shares of Repligen during the second quarter valued at approximately $25,000. International Assets Investment Management LLC purchased a new stake in Repligen during the 2nd quarter valued at $33,000. UMB Bank n.a. boosted its position in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 130 shares during the period. Lazard Asset Management LLC grew its holdings in Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 136 shares during the last quarter. Finally, Blue Trust Inc. increased its position in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 127 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.